Cormorant Asset Management, LP - Q1 2023 holdings

$1.52 Million is the total value of Cormorant Asset Management, LP's 72 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 34.2% .

 Value Shares↓ Weighting
RXDX SellPROMETHEUS BIOSCIENCES INC$177,615
-22.7%
1,655,000
-20.8%
11.70%
-24.0%
BuyMOONLAKE IMMUNOTHERAPEUTICSclass a ord$147,422
+131.5%
6,892,101
+13.6%
9.71%
+127.9%
BMEA BuyBIOMEA FUSION INC$110,733
+314.3%
3,570,872
+12.6%
7.29%
+307.7%
APLS SellAPELLIS PHARMACEUTICALS INC$89,706
+10.0%
1,360,000
-13.8%
5.91%
+8.3%
AMAM BuyAMBRX BIOPHARMA INCsponsored ads$75,820
+1329.5%
8,500,000
+263.8%
4.99%
+1306.5%
BBIO BuyBRIDGEBIO PHARMA INC$75,562
+624.3%
4,557,414
+232.9%
4.98%
+612.9%
SellARCELLX INC$49,296
-23.3%
1,600,000
-22.9%
3.25%
-24.5%
ETNB Buy89BIO INC$42,644
+31.4%
2,800,000
+9.8%
2.81%
+29.3%
NewENLIVEN THERAPEUTICS INC$42,4011,936,133
+100.0%
2.79%
RNA SellAVIDITY BIOSCIENCES INC$40,096
-34.6%
2,612,115
-5.4%
2.64%
-35.6%
PTGX NewPROTAGONIST THERAPEUTICS INC$39,1001,700,000
+100.0%
2.58%
PLRX BuyPLIANT THERAPEUTICS INC$38,410
+153.8%
1,444,000
+84.5%
2.53%
+150.0%
 ERASCA INC$32,548
-30.2%
10,813,2460.0%2.14%
-31.3%
AVTE SellAEROVATE THERAPEUTICS INC$31,499
-45.1%
1,561,696
-20.2%
2.07%
-45.9%
DSGN  DESIGN THERAPEUTICS INC$29,716
-43.8%
5,150,0000.0%1.96%
-44.7%
RAIN  RAIN ONCOLOGY INC$26,033
+9.2%
2,978,6600.0%1.71%
+7.5%
BuyIMMUNEERING CORP$23,170
+109.0%
2,386,181
+4.4%
1.53%
+105.7%
GLUE  MONTE ROSA THERAPEUTICS INC$22,542
+2.4%
2,893,7170.0%1.48%
+0.7%
VRDN SellVIRIDIAN THERAPEUTICS INC$21,624
-32.7%
850,000
-22.7%
1.42%
-33.8%
VECT  VECTIVBIO HLDG AG$21,587
-1.8%
2,536,6170.0%1.42%
-3.3%
EWTX  EDGEWISE THERAPEUTICS INC$19,656
-25.4%
2,946,8870.0%1.29%
-26.6%
AXSM SellAXSOME THERAPEUTICS INC$18,504
-26.2%
300,000
-7.7%
1.22%
-27.3%
TARS SellTARSUS PHARMACEUTICALS INC$17,867
-29.8%
1,421,422
-18.1%
1.18%
-30.9%
AXNX  AXONICS INC$17,581
-12.7%
322,2400.0%1.16%
-14.1%
VKTX BuyVIKING THERAPEUTICS INC$17,483
+165.7%
1,050,000
+50.0%
1.15%
+161.6%
 TANGO THERAPEUTICS INC$16,262
-45.5%
4,116,9490.0%1.07%
-46.4%
SRPT SellSAREPTA THERAPEUTICS INC$15,161
-41.5%
110,000
-45.0%
1.00%
-42.4%
CABA SellCABALETTA BIO INC$15,066
-17.4%
1,821,739
-7.6%
0.99%
-18.7%
RCKT  ROCKET PHARMACEUTICALS INC$14,878
-12.5%
868,5500.0%0.98%
-13.8%
KRTX SellKARUNA THERAPEUTICS INC$14,531
-32.8%
80,000
-27.3%
0.96%
-33.8%
NewSTRUCTURE THERAPEUTICS INCsponsored ads$13,712576,373
+100.0%
0.90%
SellASTRIA THERAPEUTICS INC$13,300
-45.9%
1,000,000
-39.4%
0.88%
-46.7%
MORF NewMORPHIC HLDG INC$12,233325,000
+100.0%
0.81%
RAPT NewRAPT THERAPEUTICS INC$11,928650,000
+100.0%
0.79%
CBAY NewCYMABAY THERAPEUTICS INC$11,0871,271,429
+100.0%
0.73%
OLMA BuyOLEMA PHARMACEUTICALS INC$10,695
+109.7%
3,082,000
+48.0%
0.70%
+106.5%
CYTK  CYTOKINETICS INC$10,416
-23.2%
296,0000.0%0.69%
-24.4%
PCVX SellVAXCYTE INC$10,307
-33.9%
275,000
-15.4%
0.68%
-34.9%
LBPH BuyLONGBOARD PHARMACEUTICALS IN$9,436
+36.6%
2,353,141
+11.1%
0.62%
+34.4%
STOK  STOKE THERAPEUTICS INC$9,061
-9.8%
1,087,8070.0%0.60%
-11.2%
 PRIME MEDICINE INC$9,033
-33.8%
734,3500.0%0.60%
-34.8%
NewLIANBIOsponsored ads$8,3304,250,000
+100.0%
0.55%
COGT SellCOGENT BIOSCIENCES INC$7,553
-27.4%
700,000
-22.2%
0.50%
-28.6%
PHVS  PHARVARIS N V$6,577
-28.4%
816,4600.0%0.43%
-29.6%
 VIGIL NEUROSCIENCE INC$6,038
-21.7%
616,7860.0%0.40%
-22.9%
AVIR  ATEA PHARMACEUTICALS INC$5,183
-30.4%
1,547,1810.0%0.34%
-31.5%
VERV  VERVE THERAPEUTICS INC$5,047
-25.5%
350,0000.0%0.33%
-26.7%
IDYA  IDEAYA BIOSCIENCES INC$4,806
-24.4%
350,0000.0%0.32%
-25.6%
ANNX NewANNEXON INC$4,8131,250,000
+100.0%
0.32%
GHRS  GH RESEARCH PLCordinary shares$4,738
-17.8%
593,0430.0%0.31%
-19.2%
 GREENLIGHT BIOSCIENCS HLDS P$3,973
-63.4%
9,188,6590.0%0.26%
-63.9%
 ICOSAVAX INC$3,734
-27.0%
643,8250.0%0.25%
-28.1%
ELEV  ELEVATION ONCOLOGY INC$3,709
+100.1%
1,952,0320.0%0.24%
+96.8%
BCAB SellBIOATLA INC$3,165
-89.6%
1,181,115
-67.9%
0.21%
-89.8%
PSTX SellPOSEIDA THERAPEUTICS INC$3,080
-49.5%
1,000,000
-13.0%
0.20%
-50.2%
FULC NewFULCRUM THERAPEUTICS INC$3,0821,081,490
+100.0%
0.20%
ELDN  ELEDON PHARMACEUTICALS INC$2,874
+3.5%
1,217,8820.0%0.19%
+1.6%
ALXO  ALX ONCOLOGY HLDGS INC$2,767
-59.9%
612,0790.0%0.18%
-60.6%
CNTA  CENTESSA PHARMACEUTICALS PLCsponsored ads$2,162
+24.2%
561,6000.0%0.14%
+22.4%
GLTO  GALECTO INC$2,030
+73.1%
1,020,2380.0%0.13%
+71.8%
TALS  TALARIS THERAPEUTICS INC$1,693
+84.2%
900,6490.0%0.11%
+82.0%
XFOR  X4 PHARMACEUTICALS INC$1,417
-12.4%
1,628,9800.0%0.09%
-13.9%
 BIOHAVEN LTD$1,120
-1.6%
81,9630.0%0.07%
-2.6%
SellPYXIS ONCOLOGY INC$1,093
+22.0%
272,537
-59.3%
0.07%
+20.0%
AUTL  AUTOLUS THERAPEUTICS PLCspon ads$722
-3.1%
392,1670.0%0.05%
-4.0%
EYPT NewEYEPOINT PHARMACEUTICALS INC$662225,065
+100.0%
0.04%
LPTX NewLEAP THERAPEUTICS INC$5041,481,511
+100.0%
0.03%
GRPH  GRAPHITE BIO INC$489
-26.1%
199,5470.0%0.03%
-27.3%
CMMB  CHEMOMAB THERAPEUTICS LTDsponsored ads$458
-50.3%
288,1690.0%0.03%
-51.6%
HARP  HARPOON THERAPEUTICS INC$402
+2.6%
540,6000.0%0.03%0.0%
BCEL  ATRECA INC$364
+42.7%
319,0570.0%0.02%
+41.2%
NewORCHARD THERAPEUTICS PLCspon ads new$13825,664
+100.0%
0.01%
ORTX ExitORCHARD THERAPEUTICS PLCspon ads$0-256,649
-100.0%
-0.01%
YMAB ExitY-MABS THERAPEUTICS INC$0-150,000
-100.0%
-0.05%
KROS ExitKEROS THERAPEUTICS INC$0-100,000
-100.0%
-0.32%
ACET ExitADICET BIO INC$0-600,000
-100.0%
-0.36%
ASND ExitASCENDIS PHARMA A/Ssponsored adr$0-50,000
-100.0%
-0.41%
ALT ExitALTIMMUNE INCcall$0-400,000
-100.0%
-0.44%
IMVT ExitIMMUNOVANT INC$0-400,000
-100.0%
-0.48%
ARQT ExitARCUTIS BIOTHERAPEUTICS INC$0-650,000
-100.0%
-0.64%
MRTX ExitMIRATI THERAPEUTICS INC$0-400,000
-100.0%
-1.21%
ExitAMYLYX PHARMACEUTICALS INC$0-550,000
-100.0%
-1.36%
ExitVENTYX BIOSCIENCES INC$0-1,080,643
-100.0%
-2.37%
ALT ExitALTIMMUNE INC$0-2,600,000
-100.0%
-2.86%
RVMD ExitREVOLUTION MEDICINES INC$0-1,895,066
-100.0%
-3.02%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-05-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
QUOTIENT LTD30Q3 20214.3%
ASCENDIS PHARMA A/S30Q4 20224.8%
MINERVA NEUROSCIENCES INC29Q3 20214.4%
ACCELERON PHARMA INC28Q2 20213.4%
OMEROS CORP27Q3 20216.5%
MIRATI THERAPEUTICS INC25Q4 20227.6%
BLUEPRINT MEDICINES CORP25Q3 20213.6%
APELLIS PHARMACEUTICALS INC24Q3 20238.6%
NEUROCRINE BIOSCIENCES INC24Q1 20204.6%
ROCKET PHARMACEUTICALS, INC23Q3 20232.4%

View Cormorant Asset Management, LP's complete holdings history.

Latest significant ownerships (13-D/G)
Cormorant Asset Management, LP Q1 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Immuneering CorpApril 24, 20231,996,779-
Ambrx Biopharma Inc.March 13, 202342,771,365-
Altimmune, Inc.February 14, 20232,600,000-
Arcellx, Inc.February 14, 20232,075,000-
BioAtla, Inc.February 14, 20232,499,250-
Eledon Pharmaceuticals, Inc.February 14, 20231,391,663-
GreenLight Biosciences Holdings, PBCFebruary 14, 20234,751,020-
Prometheus Biosciences, Inc.February 14, 2023700,000-
Tango Therapeutics, Inc.February 14, 20231,000,000-
VectivBio Holding AGFebruary 14, 20231,515,087-

View Cormorant Asset Management, LP's complete significant-ownership history.

Latest filings
TypeFiled
SC 13G2024-03-21
42024-03-18
SC 13G/A2024-03-18
42024-03-11
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Cormorant Asset Management, LP's complete filings history.

Compare quarters

Export Cormorant Asset Management, LP's holdings